Pressure BioSciences, Inc. (OTCQB:PBIO)

GET TOP RATED STOCK ALERTS ACTIVE TRADERS DEPEND ON

SIGN UP TODAY FOR FREE NEWS DRIVEN ALERTS
Long-time Uncle Bud's Supporter, Multi-Award Winning Singer, Songwriter, and Actress Toni Braxton (Photo: Business Wire)
  •  Strategic Merger Combines Uncle Bud’s Globally-Recognized Brand of 70 Products and 865K Member On-Line Community with PBIO’s Strong Scientific Capabilities, Technology Platforms, and Patent Estate
  • Toni Braxton – Multiple Grammy Award Winner and Long-Time Uncle Bud’s Advocate – Continues as Spokesperson for the Combined Company

  

South Easton, MA – January 11, 2024 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a pioneer in the development and distribution of broadly enabling pressure-based instruments, consumables, and specialty process development and testing services across global industries, including nutraceuticals, food and beverage, health and wellness, cosmetics, biotherapeutics, and more, today announced the execution of a definitive agreement to acquire globally-renowned natural health and wellness leader Uncle Bud’s.  Upon the closing of the transaction, the combined company intends to become a leading provider of topicals and other consumer products, leveraging PBIO’s UltraShearTM technology platform for nanoemulsified products that deliver industry-leading speed of action and bioavailability.

 

Long-time Uncle Bud's Supporter, Multi-Award Winning Singer, Songwriter, and Actress Toni Braxton (Photo: Business Wire)Toni Braxton, multi-award-winning singer, songwriter, actress, and long-time customer and spokesperson for Uncle Buds Hemp said: “I am thrilled to be a part of this exciting acquisition of Uncle Bud’s, a brand that I have loved from the beginning. Uncle Bud’s has always prioritized quality and innovation, and it’s great to see them merge with a company that shares the same vision. I look forward to continuing my journey with them on this new venture and I am eager to be part of the company’s growth and other exciting things to come.”

 

Garrett Greller, Director of Marketing and Co-Founder of Uncle Bud’s, said: “This acquisition marks a transformative step for Uncle Bud’s. With a commitment to quality, effective solutions, and an impressive lineup of celebrity partners, Uncle Bud’s has democratized Hemp & CBD wellness. Now, joined with PBIO, we are set to innovate across multiple sectors such as pain relief, sexual wellness, skin care, beverages, food, & pet care to name a few. To achieve this goal, Uncle Bud’s is leveraging PBIO’s scientifically proven UltraShear™ platform as a commitment to elevating high quality health & wellness to new heights.”

 

Bruno Schiavi, President and Co-Founder of Uncle Bud’s, commented: “In the spirit of Uncle Bud’s mission to provide trusted, affordable, and accessible wellness solutions, this merger with PBIO is a game-changer. The UltraShear platform offers a unique opportunity to develop a range of wellness products with superior bioavailability and clean-label attributes. Together, Uncle Bud’s and PBIO are not only bringing innovative products to the market but also educating and leading the industry towards a brighter, healthier future.”

 

Ric Schumacher, President and CEO of PBIO, added: “We are delighted to welcome the experience and expertise of the Uncle Bud’s team into the PBIO family, as well as their broad customer network. They bring proven skills in marrying brand creation and celebrity spokesperson superpower with planning and execution of product introductions and growth strategies.  This dynamic combination is what we have been seeking to accelerate the penetration of the UltraShear technology through multiple markets.  As we embrace this opportunity, we are looking at several powerful new product line opportunities that are ripe for transformative product delivery, leveraging the power of PBIO’s revolutionary UltraShear platform.”

 

Jeff Peterson, PBIO’s Chairman concluded: “This pivotal forward integration strategy for our UltraShear platform has been our objective for some time, and Uncle Bud’s is precisely the kind of empowering partner that we have been seeking.  The integration of Uncle Bud’s into PBIO’s financials is expected to be immediately accretive and a major accelerator to PBIO’s top line revenue growth.  The combined companies will be ideally positioned to attract new growth investment, rapidly strengthen the balance sheet, accelerate our path to profitability within 2024, and to catalyze our drive to uplist to NASDAQ or NYSE even earlier in 2024. Our team, and our dedicated investors, are rightfully excited over the accelerating growth opportunities now solidifying for 2024 and beyond!”

 

Transaction Terms

 

Under the terms of the agreement, UB stockholders will be entitled to receive preferred stock of PBIO that is convertible into shares of PBIO common stock and no cash at the closing of the transaction.  In addition, the parties agreed to an earnout for additional shares of PBIO common stock based on the achievement of revenue and net profit results in 2024.  Such shares will be subject to standard restrictions on resale.

 

Closing Conditions

 

The transaction has been unanimously approved by the Boards of Directors of both companies and is subject to customary closing conditions. Subject to the satisfaction or waiver of the closing conditions, the transaction is expected to close by January 19, 2024.

 

About Uncle Bud’s

 

Officially launched in September 2018 with one hero product, Uncle Bud’s has experienced unequivocal growth. As a leader in the Hemp and CBD space, Uncle Bud’s takes pride in being Made in America, GMO Free, Cruelty Free and Leaping Bunny Certified. The full range includes Hemp & CBD products for pain relief, skincare, personal care, and even pet care – all retailing under $45.To learn more about Uncle Bud’s visit unclebudshemp.com as well as their associated Instagram: @UncleBuds_Hemp; Facebook: @UncleBuds_Hemp and Twitter: @UncleBuds_Hemp.

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilize both constant and alternating pressure.  Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids.  It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.

 

Forward Looking Statements

 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI, Uncle Bud’s, and this press release, please click on the following website links:

http://www.pressurebiosciences.com
http://www.unclebudshemp.com

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences Secures Pivotal Cosmeceuticals Partnership for UST Platform with Dr. Denese SkinScience, 20-Year Leader with Over $0.5 Billion in QVC Sales

Collaborative UST-Driven Research and Development Agreement Announced with Dr. Adrienne Denese (QVC Icon, Skincare Visionary, Anti-Aging Pioneer, & Creator of Award-Winning SkinScience Labs) Targets Revolutionary Nanoemulsion-Driven Performance in New, Proprietary Skincare Products

  

South Easton, MA –  August 24, 2022 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and specialty testing services to the worldwide cosmetics, nutraceuticals, biotherapeutics, and food/beverage industries, among others, today announced the Company’s agreement to team with science-driven skincare industry leader Dr. Adrienne Denese, M.D., Ph.D., the creator and President of Dr. Denese SkinScience  – one of the most successful, highly rated, award winning, and longest lasting skincare lines in the history of QVC.

 

Under the two-year Collaborative Research and Development Agreement (“CRA”) between PBI and Dr. Denese SkinScience, the two companies will prioritize specific skincare projects to pursue.  Statements of Work (“SOW”) will be developed, with approved budgets, timetables, and remuneration formulas for both companies. PBI and Dr. Denese have already agreed to focus on the use of PBI’s unique Ultra Shear Technology™ (“UST™) nanoemulsification platform to enhance existing and develop new skincare products for Dr. Denese SkinScience.  The UST platform’s proven ability to process oil-based active ingredients (e.g., retinol, vitamins, anti-oxidants) into effectively water-soluble formulations is expected to offer more effective absorption, bio-availability, and therapeutic benefits to users of Dr. Denese SkinScience existing and new quality-leading skincare products.

 

Dr. Adrienne Denese commented: “Having achieved over $560 million in QVC sales over a 20-year period, I am very proud of our company’s track record, my team, and the very loyal customer base that we have built under the Dr. Denese SkinScience brand. My mission has always been to develop and deliver the highest quality skincare products with life-changing effectiveness. Therefore, I could not be more excited at the prospect of teaming up with PBI and putting their UST platform’s remarkable breakthrough in nanoemulsion effectiveness to work, in new generations of skincare products.  I believe our partnership offers the opportunity to make new category-changing products that I have dreamed about, to enhance selected existing products, and to take these revolutionary new products to much greater heights and to many new customers through our existing QVC, e-commerce, and Amazon channels, as well as through our new Costco affiliation.”

 

Mr. Richard T. Schumacher, President and CEO of PBI, observed: “From 2019 – 2021, Dr. Denese averaged close to $20 million per year in total sales.  In 2022, with help from new channel partner Costco, sales are expected to increase significantly. The  launch of a new generation of products processed by PBI’s patented UST platform, for the first-time ever in the cosmeceuticals area, is planned for 2023, which we expect to result in a very fulfilling and exciting year for Dr. Denese and her loyal customers – and for PBI!”

 

Mr. Schumacher concluded: “Although final determination of the order of development of these new and enhanced products is yet to be announced, both Dr. Denese SkinScience and PBI understand that these are potential game-changers in an industry whose 2021 global market size was estimated to be over $130 billion.  We look at this partnership as an opportunity for multi-million dollar accretive revenue growth for both companies over the next two years, with the potential to dramatically enhance the growth trajectory and profitability of both Dr. Denese SkinScience and PBI for years to come.”

 

Mr. Jeffrey N. Peterson, Chairman of the PBI Board, added perspective: “Dr. Adrienne Denese is an accomplished doctor, scientist, businesswoman, and skincare visionary.  Her life’s mission has been to help women look and feel younger, and to live heathier lives. We noted from the outset of or our work with Dr. Denese, that her immutable priority has always been to effectively provide the highest quality therapeutic ingredients to her customers. Through hard-work, tenacity, and an innate ability to deliver what the market needs, Adrienne has created a skincare line that has already become a titan in its field, as one of QVC’s most successful, highly rated, award winning and longest lasting skincare lines. It continues to enjoy some of the highest rates of repeat, any-time, and automatic customer reorder rates of skincare products in QVC’s history.”

 

Mr. Peterson concluded: “Our UST platform is a transformational technology that we believe will alter the basis of competition for products across many industries, as it becomes the new manufacturing standard in cosmeceuticals and other industries.  For our initial entry into the cosmeceuticals and personal care products sector, it was important that we partnered with an industry leader driven by science. Dr. Denese fulfilled that promise, with products sold not just in the U.S., but throughout the world.  She is a visionary, innovator, and global success story.  We are honored to partner with her and her amazing team.  As the first cosmeceuticals company to embrace and capitalize on the powerful advantages of the UST platform for nanoemulsions processing, Dr. Denese SkinScience continues to deliver visionary leadership in setting unrivaled standards for quality and performance – a potent example for UST impact that will resonate across industries.”

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences’ Ultra Shear Technology™ Positioned for Critical Enabling Role in Global $41 Billion (2027) Plant Protein Beverage Market

Recent Study Published by The Ohio State University Illuminates Unique Capabilities of PBI’s UST Platform for Optimal Formulation and Processing of New and Existing Plant Protein-based Beverages

 

South Easton, MA – June 14, 2022 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and process development services to the worldwide food and beverage, biotherapeutics, and personal wellness industries, among others, today announced a pivotal peer-reviewed scientific publication highlighting the use of PBI’s patented Ultra Shear Technology™ (“UST™”) platform in the production of protein-enriched milk containing a novel emulsified plant-protein suspension.  J.J. Janahar, et al., from The Ohio State University (“Ohio State”) College of Food, Agricultural, and Environmental Sciences (“CFAES”) in a study published in the high impact journal Food Hydrocolloids, Volume 131, reported that UST successfully created stable suspensions of milk-pea protein blends in microscopic particle sizes – the objective required for commercially-suitable products, and a significant achievement that could not be reached through existing high-pressure processing (HPP) or thermal processing techniques alone.

 

Efforts to produce satisfying, nutritionally-efficient and sustainable food options are driving one of the fastest growing food and beverage markets worldwide.  Creating cost-effective and sustainable food alternatives that appeal to the expectations and preferences of global consumers has pushed researchers to examine many alternative protein enrichment sources, including the use of almonds, oats, soy, coconuts, peas, etc.  Unfortunately, many of these protein sources lack the creaminess, texture, sweetness, or other attributes that drive consumer acceptance. The blending of plant and dairy components to achieve the desired consumer appeal presents enormous market opportunities.  Pea protein is of particular interest because of its high nutritional value and low cost – but it is highly insoluble in water and thus has been minimally used in protein drinks to date.  PBI’s proprietary UST platform combines very high pressure and precisely controlled extreme shear forces to provide food scientists the toolset needed to successfully blend dairy and pea protein (two products which naturally resist mixing) into a sensory-appealing, nutritional, and long-term stable plant protein-based beverage.

 

PBI and Ohio State are co-leading a Food Industry Consortium whose mission is to introduce worldwide food and beverage companies to PBI’s UST platform for the production of higher quality, longer shelf-life, and safer liquid foods and beverages.  PBI’s UST platform is the critical tool that enables and achieves targeted reductions and dependency on chemical additives or damaging heat relied upon in current processing methods. UST is pivotal in enabling the production of natural, organic, healthier, more nutritious, “clean-label” products that offer greater appeal to modern consumers.

 

Mr. John B. Hollister, Director of Marketing and Sales expanded: “Ohio State and PBI have initiated an aggressive outreach program to a number of preeminent food & beverage companies globally and expect to welcome many Consortium members during the second half of 2022. Members will help direct and focus Ohio State and PBI efforts across a diverse universe of prospective liquid food and beverage products, with emphasis on microbiology, stability, nutrition, sensory qualities, and increased bioavailability. UST applications development will also extend into nutraceutical products, such as infused water, functional sports beverages, and other health-focused products of high interest to consumers and producers.” (North Equities Video Interview – Hollister).

 

Mr. Hollister continued: “With the recent publication of the Ohio State data, an additional and very exciting application of interest is plant protein-based beverages. As new and commercially-relevant UST applications continue to be demonstrated, and Consortium members utilize their first rights to license UST for their own use, Ohio State and PBI will both benefit from resulting royalty streams. PBI will also benefit from equipment leases and consumables sales.”

 

Dr. Edmund Y. Ting, Senior VP of Engineering at PBI, and a pioneer in the development of high pressure-based food technologies, commented: “Many beverage ingredients that are beneficial to convenience, health, and desired sensory characteristics are not soluble in water, e.g., pea proteins.  However, UST’s ability to achieve micro/nano particle size suspensions of such plant proteins offers enticing solutions for the use of these essential, water-insoluble ingredients.  Interestingly, such UST-processed suspensions can be optimized to provide thickening viscosity for certain products, which can result in improved stability, nutritional value, and consumer appeal.  Thus, UST’s ability to formulate complex micro/nano emulsions and suspensions will give manufacturers multiple additional options for health and wellness products. While we have previously demonstrated that UST makes fantastic nanoemulsions, there are even more applications where microemulsions as well as nano/micro suspensions are practical and useful for products and product concentrates.”

 

Mr. Richard T. Schumacher, President and CEO of PBI, summarized: “The quest for finding alternative beverages that are healthier and environmentally sustainable but also appealing to the palate – such as plant protein-based drinks – is a rapidly growing market estimated to reach $41B by 2027 (MDC Market Report).  We are currently in discussions with industry leaders in this market, as well as companies that want to use UST to make high quality nanoemulsions to add vitamins, antioxidants, nutraceuticals, etc. to their beverages.  The recent Ohio State results on UST-processed micro/nano plant protein milk suspensions, as well as previously released data om UST-enhanced nanoemulsions, support our confidence that UST has the potential to become an essential tool in future beverage development, as well as in other health-related and consumer markets (TechTalks Video). We continue to look forward to the planned Q3/Q4 2022 commercial release of the UST platform.”

 

Sponsorship of UST development by the U.S. Department of Agriculture’s NIFA program is deeply appreciated.

 

PBI’s June 30th Webinar Participation

 

On June 30th at noon, PBI will participate as an invited panelist in a FORCE Family Office Webinar.  Mr. Schumacher will represent PBI.  Other panelists are also being invited. The Webinar will be sponsored by FORCE Family Office and will be moderated by Mr. Steven Saltzstein, CEO of FORCE.  As further information becomes available, it will be placed on the Force Family Office and Pressure BioSciences websites.  If you would like to receive an invitation, please contact us directly.

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

 

SOURCE:  Pressure BioSciences, Inc.

Pressure BioSciences Ultra Shear Technology Commercialization Achieves Key Milestone: Production-Scale System Commissioned at Ohio State to Serve Food Industry

Installation of BaroShear MAX UST System in Acclaimed The Ohio State University Food Pilot Plant Will Introduce Global Food Industry to Preparation of Safer, More Nutritious Liquid Foods and Beverages

 

South Easton, MA – January 27, 2022 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and process development services to the worldwide food and beverage, biotherapeutics, and personal wellness industries, among others, today announced the commissioning of its first production-scale, patented Ultra Shear Technology™ (“UST™”) platform.  The BaroShear MAX UST processing system was installed and commissioned in The Ohio State University College of Food, Agricultural, and Environmental Sciences (“CFAES”).  Along with the previously announced formation of the Food Industry Consortium, co-led by PBI and Ohio State, this completes one of the last remaining critical milestones in the UST platform deployment at Ohio State to serve the global food industry.

 

The Consortium’s mission is to help companies manufacture higher quality, longer shelf-life, and safer liquid foods and beverages. Utilizing PBI’s proprietary UST platform, producers can reduce/remove chemical additives and damaging heat in current processing methods, enabling the production of healthier, more nutritious products with greater appeal to modern consumers.   The Consortium is open to food companies worldwide.  Ohio State and PBI plan to initiate an aggressive outreach program in the Spring 2022 and expect to welcome a global group of preeminent food & beverage companies as Consortium members shortly thereafter. Members will help direct Ohio State and PBI efforts across a universe of prospective liquid food and beverage products, with emphasis on microbiology, stability, nutrition, sensory qualities, and increased bioavailability. UST applications development will also extend into nutraceutical products, such as infused water, functional sports beverages, and other health-focused products of high interest to consumers and producers. Consortium members will have a first-right to license new applications and methods.

 

Dr. Edmund Y. Ting, Senior VP of Engineering at PBI, and a key innovator in the development of high pressure-based food technologies, commented: “Over the past 20 years, high pressure processing (“HPP”) has emerged as a highly successful, clean-label approach for food quality and safety. The HPP market was estimated at $15.5 billion in 2019.  HPP is a versatile technology, but it does not employ critical fluid shear forces like UST, which are essential when particle or droplet size reduction is required for better stability, texture, taste, and bioavailability. Our UST platform uniquely combines the benefits of high hydrostatic pressure, extreme fluid shear, and controlled temperature to achieve these results. Food proteins and lipids, processed by UST, result in true nanoemulsions with improved appearance, taste, smell, texture, nutrition, stability, and bioavailability – all of which are important attributes to liquid foods, such as sauces, beverages, and even ice cream.  Importantly, UST not only can produce the highest quality nanoemulsions, but this innovative process can also help destroy bacteria and other pathogens, and reduce/eliminate the need for chemical additives, thus increasing food safety.”

 

Dr. Alexander V. Lazarev, Chief Science Officer of PBI, added: “We believe the ability to modify physical attributes and safety/stability through the physics of shearing and pressure, rather than chemical additives and heat, will create a multitude of new opportunities in the development of new or improved products in other areas, such as cosmetics, nutraceuticals, and pharmaceuticals. Additionally, nanoemulsions are already beginning to play a major role in advanced therapeutics.”

 

Mr. Richard T. Schumacher, President and CEO of PBI, explained: “We expect to begin placing commercial processing units into the market during the third/fourth quarters of 2022, under a leasing and licensing model.  As new and commercially-relevant UST applications are demonstrated, and Consortium members utilize their first rights to license them for their own use, Ohio State and PBI will both benefit from resulting royalty streams. PBI will also benefit from equipment leases and consumables sales. In addition, PBI will drive the commercialization of these new applications amongst non-Consortium food companies worldwide and through multiple other major industries beyond food and beverages.”

 

Sponsorship of UST development by the U.S. Department of Agriculture’s NIFA program is deeply appreciated.

 

PBI’s January 20th Webinar Participation

 

On January 20th, PBI participated as an invited panelist in a FORCE Family Office Webinar on Innovations and Advancements in the $4.6 Billion CBD Market.  Mr. Schumacher represented PBI.  Other panelists included: (i) Dr. Christopher Hudalla, the founder and CSO of ProVerde Laboratories, one of the most respected cannabis analytical testing laboratories in the U.S. Dr. Hudalla was recently voted as one of the top 10 influencers in the cannabis sciences industry, and (ii) Mr. Richard “Ricky” Wright, the Founder and CEO of the Alkaline Water Company (NASDAQ: WTER).  Alkaline Water has recently launched a new CBD-infused bottled water to provide functional benefits to consumers.  The Webinar was sponsored by FORCE Family Office and was moderated by Mr. Steven Saltzstein, CEO of FORCE.  Please click here to access the full Webinar: Innovations & Advancements in the CBD Market. 012021.

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

 

SOURCE:  Pressure BioSciences, Inc.

Pressure BioSciences New Eco-Friendly Agrochem Subsidiary Receives Over $1,000,000 in Orders in First Month of Operations

PBI Agrochem Integration into the Sales Channels of Its Planned Asset Acquisition of a Global,  Environmentally Responsible Agrochem Company is Expected to Result in a Significant Q3 2021 Impact

 

South Easton, MA, August 12, 2021 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today announced that its newly-formed agrochemicals subsidiary – PBI Agrochem, Inc. – has received initial purchase orders for over $1M of eco-friendly agrochemical products for delivery in 2021.  Just three weeks ago, the Company announced the formation of its new agrochemicals division in anticipation of the planned asset acquisition of a global agrochemicals products business focused on organically natural and environmentally responsible products.

 

PBI’s President and CEO Richard T. Schumacher explained the fast development of early sales: “With integration planning for this acquisition well underway, PBI Agrochem placed an initial order for specialized, proprietary bulk material in July and began establishing U.S. warehousing, processing, and final product packaging facilities. Our objective was to insert PBI Agrochem into the supply chain and sales channels of our acquisition target, in order to capture early sales revenues that we believe could have an immediate, accretive impact upon PBI’s overall operating results.  These efforts have resulted in over $1M in 2021 customer orders for eco-friendly and effective agrochemical pest control and growth stimulant products.”

 

Mr. Schumacher continued: “We anticipate that the delivery and booking for most of these orders will occur during the third quarter 2021. PBI investors who have followed and supported the Company through recent years understand that this new incremental revenue from PBI Agrochem represents a potential doubling (or more) of quarterly revenues, when added to sales of PBI’s existing core products and services. With additional orders expected to arrive over the coming weeks and months, we believe Q4 2021 could substantially exceed the results of Q3 2021. Our new agrochem sales are expected to accelerate PBI’s rapidly improving growth trajectory and should contribute substantially towards our planned transition to profitability by the end of 2022.”

 

Mr. John B. Hollister, Director of Sales and Marketing at PBI, said: “The market potential in agrochemicals is enormous, driven by the intersection of burgeoning global population growth and accelerating environmental consciousness and priorities. Our positioning in organically natural and ecofriendly product solutions places PBI squarely within the hottest growth generation in this sector.  Closing on over $1M of orders in the first month of PBI Agrochem operations is a welcome signpost on the road to major growth and profitability for our agrochem operations.  The broad array of eco-friendly products being integrated into PBI will address a diversity of agrochem client needs throughout the year, from fertilizing young plants, to mitigating microbial and larger animal threats, to enhancing the appearance and appeal of finished produce.”

 

PBI’s Board Chairman Jeffrey N. Peterson commented on the synergies achieved in PBI’s move into agrochemicals: “The creation of many organically natural and effective, environmentally-friendly agrochemical products is typically achieved through utilization of essential oil active ingredients extracted from plants, such as the already popular use of orange peel essential oil in ant sprays. PBI’s breakthrough Ultra Shear Technology™ (UST™) platform, for creation of extremely low-droplet size nanoemulsions of oils in water, offers added value for a new generation of products with improved effectiveness and economics, allowing less active material to deliver higher effectiveness when applied or consumed.  We are aggressively driving the creation of pioneering partnerships around UST in application sectors from pharmaceuticals to nutraceuticals to food/beverage and many more areas, as PBI’s core strategy for growth and profitability. We have singled out agrochemicals for a more aggressive forward integration into an applications sector for UST, in a bid to accelerate the cycle of education, trial, market demonstration, product differentiation, and uniquely advantaged growth.  We are delighted to be sharing these insights into PBI’s expected accelerating growth trajectory and path to profitability with our loyal investor base.”

 

The asset acquisition is subject to certain conditions, including the completion of all due diligence and acquisition financing.

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

SOURCE:  Pressure BioSciences, Inc.

Pressure BioSciences UST-Enabled Nanoemulsions Soar Past One Year Stability Goal;  Results Open Explosive Growth Potential for Water-Soluble CBD-Infused Beverages Worldwide

UST Nanoemulsions of CBD Deliver High Water-Solubility and Over One Year Storage Stability with No Degradation;

 

UST Platform Primed to Revolutionize Food & Beverage, Biotherapeutic, Nutraceutical, and Agrochem Products

 

South Easton, MA –  July 13, 2021 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and innovative services to the worldwide biotechnology, biotherapeutics, cosmetics, nutraceuticals, agrochemical, and food & beverage industries, today announced that processing hemp-derived cannabidiol (“CBD”) with its Ultra Shear Technology™ (“UST™”) platform produces high quality water-soluble nanoemulsions of CBD oil in water with the critically important benefit of scientifically proven long-term stability.  Specifically, the Company reported breakthrough results in which its UST processing platform produced the consistent and extremely fine nano-dispersions of CBD oil in water that are required to achieve product stability in excess of twelve months, under both cold and room temperature storage conditions, even with multiple freeze-thaw cycles, without any visible or measurable deterioration of the nanoemulsified product.

 

CBD is a non-psychoactive, oil-soluble compound extracted from the cannabis plant, and is typically marketed in a plant oil solution. CBD has been widely reported to offer numerous health benefits from stress and anxiety relief, to Schizophrenia, decreased seizures, muscle, joint, cancer and other pain, and reduced inflammation. Because CBD is oil-based, its ingestion or topical application typically results in poor absorption in water-based living systems, like humans. For example, the World Health Organization estimated CBD bioavailability from oral delivery of oil-based formulations was just 6%.  That means most ingested CBD is wasted, passing through the body without being absorbed. Consequently, there is enormous interest in the development of truly water-soluble CBD, to achieve efficient dosing delivery, absorption, and bioavailability from foods and beverages.

 

ProVerde Laboratories is one of the most advanced analytical testing service laboratories in the country offering testing of cannabis-derived materials, including cannabinoid profiling and particle size characterization.  Dr. Christopher Hudalla, President and Chief Scientific Officer of ProVerde Labs provided powerful perspective: “We test hundreds of cannabis products on a regular basis, and the overwhelming diversity of so-called water-soluble products that we test consistently suffer from poor particle uniformity and a lack of long-term stability.  This often results in cannabinoid degradation, phase separation, coalescence and or sediment formation.  The introduction of a new technology platform that can consistently produce the necessary ultra-low droplet size nanoemulsions required to deliver reliable shelf life of over one year, including resistance to freeze-thaw challenges, will be a pivotal inflection point and an explosive growth opportunity in the CBD and cannabis-derived products industry.”

 

Mr. John Westlake, Founder and President of Canopy CBD Farms, LLC., further confirmed: “Scientific data strongly supports the critical need for hemp-derived CBD oil to be processed into water-soluble nanoemulsions to achieve the highest levels of absorption and bioavailability with optimal dosing safety and overall product cost efficiency for manufacturers and consumers.  For commercial success, these CBD nanoemulsions must also be long-term stable, to help ensure that the CBD-containing product has the best opportunity to achieve its promise after months in distribution and shelf storage.  In my many years in the cannabis market, this is the first time I have observed such an accomplishment: a high quality nanoemulsion of CBD oil in water with over one year of real time, rock-solid, cold and room temperature stability, even following multiple freeze-thaw cycles.  These results are highly impressive.”

 

Mr. Gary B. Smejkal, Senior Research Scientist at PBI, explained the Company’s breakthrough: “Achieving long-term stability of nanoemulsions requires production processes that attain consistent, extremely low oil droplet sizes in water.  Our unique formulations and patented UST processing platform use unprecedentedly high pressures to achieve repeated cycles of extreme shearing forces at controlled temperatures and flow rates, which we believe deliver the highest quality and most long-term stable CBD nanoemulsions available in the world today.”

 

Mr. John B. Hollister, Director of Sales and Marketing at PBI, expanded on the opportunity: “CBD-containing nanoemulsions created by our innovative and proprietary UST processing platform have the potential to revolutionize the rapidly growing cannabis market, not just in food and beverage, but in multiple other areas as well, including biotherapeutics, nutraceuticals, agrochem, and cosmetics.  From truly clear, water-soluble infusions in beverages that are cold and room temperature long-term stable, to predictable dosing with much faster onset of action than other edible forms, we believe the benefits and appeal for consumers will be tremendous.  We are excited to have achieved this historic milestone of surpassing one-year of real time cold and room temperature stability and look forward to the impending commercial release of our initial UST-based nanoemulsion system by or before the end of 2021.”

 

With a projected compounded annual growth rate (CAGR) of 21.2% from 2021 to 2028, the global CBD market is expected to grow from USD $2.8B in 2020 to USD $13B in 2028.

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

 

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

SOURCE:  Pressure BioSciences, Inc

Pressure BioSciences Novel UST™ Platform Delivers Breakthrough Nanoemulsion Processing for One of the World’s Most Potent Antioxidants - Astaxanthin

Unprecedentedly Tiny, Uniform, and Stable Nanoemulsified Oil Droplets Containing Astaxanthin Expected to Significantly Increase Oral and Topical Absorption of this Antioxidant 6,000x More Powerful Than Vitamin C

 

South Easton, MA – July 1, 2021 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced the application of its Ultra Shear Technology™ (“UST™”) platform for the development of more potent formulations of wide-ranging nutraceuticals of high therapeutic value, allowing for more controlled dosing and opportunities for lower cost solutions for both manufacturers and consumers.  Specifically, the Company reported breakthrough results in processing one of the most powerful antioxidants known to science, astaxanthin (“AsX”), in extremely fine and uniform, monodisperse nanoemulsions of oil in water – critically important for fast and efficient absorption by the water-based biochemistry of humans and animals.

 

Astaxanthin is a natural red pigment produced by the microalgae Haematococcus pluvialis.  It is responsible for the red coloration of krill and other crustaceans, and in turn, the familiar coloration of salmon and flamingos which feed on them.

 

As an antioxidant, AsX is 6000 times more powerful than vitamin C, 800 times more powerful than CoQ10, and 100 times more powerful than vitamin E [1].  In clinical studies, AsX has been shown to neutralize free radicals, greatly reducing oxidative stress [2], enhance natural immune response [3], improve muscle endurance and exercise performance [4], support cardiovascular, neural/cognitive and ocular health [5, 6, 7], protect skin against UV damage and premature aging [8], favorably modulate specific cell signaling pathways involved in cancer cell death [9], and even improve sperm motility in male infertility.   Recent studies have suggested that AsX may help alleviate progression of COVID-19 into severe cytokine storm condition [10,11].  Further, AsX can cross the blood–brain barrier and has been shown to increase gene expression of several proteins known to be involved in injured brain recovery [12].

 

It is particularly important for antioxidants be water-soluble, allowing them to circulate freely through the blood.  However, because AsX is oil-based and intrinsically water-insoluble, oral/gastrointestinal and topical absorption of AsX is typically less than 10%, unless it is effectively solubilized in dietary fats or provided in a lipid-based formulation [13].  Even then, AsX in oil is typically delivered in large droplets that pass through the body with very low overall absorption efficiency.

 

Gary B. Smejkal, Senior Research Scientist at PBI, explained the breakthrough achieved by the Company: “Nanoemulsions produced by PBI’s UST platform encapsulate AsX in extremely small oil droplets ranging in size from 30-60 nm in diameter [14].  Because these particles are so small, they do not scatter light and thus appear as clear ruby red liquids that disperse freely in water or other clear beverages.  The enhanced oral bioavailability of AsX corresponding to droplet size reduction is well-established and has been published [15].

 

Mr. Smejkal continued: “Our initial stability studies have already shown that UST-processed AsX nanoemulsions are stable for at least four months at room temperature without any measurable change in oil droplet size, coalescence, or phase separation.  We used AsX as a model compound to demonstrate the power of our UST platform technology.  Our approach will be readily suitable to prepare nanoemulsions of other carotenoids and a wide range of fat-soluble vitamins and dietary supplements. We believe that the implications of PBI’s UST platform for AsX and for a multitude of other oil-soluble nutraceuticals will undoubtedly be dramatic in the marketplace.”

 

Mr. Richard T. Schumacher, President & CEO of PBI, commented: “The global astaxanthin market size was estimated at USD 1.0 billion in 2019 [16].  PBI is laser-focused on exploring the opportunities for our UST platform to profoundly alter the effectiveness and competitiveness of a great number of lucrative nutraceutical products.  We have already begun discussions with prospective partners worldwide who are interested in using UST for production and commercialization of astaxanthin and other nutraceutical nanoemulsions.  We remain optimistic that we will meet our stated goal of releasing our initial UST-based instrument to the market before the end of 2021. As previously announced, we intend to make this system available through a lease/royalty business model.”

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

 

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

SOURCE:

Pressure BioSciences, Inc.

Pressure BioSciences and The Ohio State University Announce Food Industry Consortium to Advance Commercialization of PBI’s Ultra Shear Technology

Academia-Industry Partnership to Support Improvements in UST Applications and Allow Global Food Companies Access to UST for Preparation of Safer, More Nutritious Liquid Foods and Beverages

 

South Easton, MA – February 24, 2021 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, nutraceuticals, cosmetics, agriculture, and food & beverage industries, today announced it has entered into a wide-ranging agreement with the College of Food, Agricultural, and Environmental Sciences (“CFAES”) at The Ohio State University (“Ohio State”).  Under the Agreement, bench-top and floor model test systems of PBI’s patented Ultra Shear Technology™ (“UST™”) platform for the high shear processing of liquids under controlled temperature and pressure conditions will be set up in the acclaimed Ohio State food pilot plant. To help introduce the potential of the UST platform for strategic innovation to global food companies, PBI and Ohio State have announced the formation of a food industry consortium (the “Consortium”), whose members will have access to the UST test systems in the pilot plant, as well as licensing rights to the UST platform.  The Consortium is the result of research initially sponsored by the USDA NIFA for which we gratefully acknowledge their support.

 

The primary goals of the Consortium are to develop and improve new commercial applications of UST; help develop the scientific support needed to address possible regulatory issues; and to experience first-hand UST product development and pre-commercialization efforts. The Consortium will be open to food companies worldwide. Consortium members will help direct the scientific efforts of Ohio State and PBI across a universe of prospective liquid food & beverage projects.  Topics of interest will include spore inactivation and other pathogen and spoilage factor control; enhanced taste, smell, and other sensory qualities; and the formation of highly stable products suitable for ambient temperature storage and distribution.

 

Research studies suggest that under ultra shear conditions, unique microbiological, textural, sensory, and other benefits are possible.  These benefits can lead to safer, higher quality, and more nutritious consumer-friendly “clean-label” (free of unwanted chemical additives) liquid foods and beverages.  Consortium members receive a first right to non-exclusively license all new applications for commercial utilization in their own products.  PBI has the right to license all new IP to non-members of the consortium worldwide.

 

Dr. Edmund Y. Ting, Senior VP of Engineering at PBI, and a pioneer in the development of high pressure-based, non-thermal methods to make food and beverages safer, commented: “Over the past two decades, high pressure processing (“HPP”) has emerged as a highly successful, clean-label approach for food safety and improved shelf-life.  Products such as juice, guacamole, and deli meats are routinely processed today using HPP.  However, HPP does have limitations and drawbacks, particularly the inability to produce high quality, high stability homogeneous liquid products via the combination of fluid shear, brief shear induced heating, and continuous output compatible with modern aseptic packaging.”

 

Dr. Ting continued: “Our UST platform uniquely combines the benefits of HPP with extreme liquid shearing forces and controlled temperature to accomplish results such as inactivation of food-borne bacteria and modifications leading to improved stability, texture, taste, and nutrition.  The ability to modify structure through physical stress will create many new opportunities in the commercialization of liquid foods and beverages, as well as in nutraceuticals and pharmaceuticals.”

 

Professor V.M. (“Bala”) Balasubramaniam, Professor of Food Engineering at Ohio State, said: “We expect the Consortium supported studies conducted by the Ohio State and PBI teams will demonstrate that the UST platform can be used to achieve significant improvements in the processing of healthier, safer, less costly, and more pleasing beverages, sauces, condiments and other liquid foods. We also expect such studies will support the ability of UST processing to significantly extend the stability of liquid foods and beverages at room temperature.  In addition to a more satisfied consumer, these efficiencies will deliver important cost savings to suppliers in more efficient product distribution costs without cold chain requirements. In addition, such research efforts will help the student education and future workforce training on various advanced food technologies including ultra-shear technology.”

 

Known internationally for his research on high-pressure and other types of nonthermal processing, or safely processing food using significantly less heat, Dr. Bala leads a multidisciplinary team of microbiologists, chemists, and nutritionists, investigating innovative food technologies and partnering with industry to implement them commercially. He holds joint appointments in the CFAES departments of Food Science and Technology, and in Food, Agricultural and Biological Engineering.  Other distinguished members of the CFAES research team include Ahmed Yousef, Professor of Food Microbiology; Rafael Jimenez-Flores, the J.T. “Stubby” Parker Endowed Chair in Dairy Foods; and Christopher Simons, Associate Professor of Sensory Science.

 

Mr. Richard T. Schumacher, President and CEO of PBI, explained: “This new Consortium will welcome a global group of preeminent leading food & beverage companies as members.  Each will contribute annually towards the Consortium’s operations, with funds supporting research and development at both PBI and Ohio State, while participating as an advisory council to nominate, prioritize and direct UST applications development amongst the myriad opportunities that invite our attention. As new and commercially relevant UST applications are demonstrated and members utilize their first rights to license them for their own use, Ohio State and PBI will both benefit from resulting royalty streams. PBI will also benefit from instrument leases and consumables sales. In addition, PBI will drive the exploitation of these new application innovations amongst non-Consortium companies worldwide.”

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:        http://www.pressurebiosciences.com

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences Achieves Critical Milestone in Revolutionary Nanoemulsification Technology Development; Enters Production Era for Commercial System Development

Company Locks-in Final Design Specifications, Begins Initial Build of Proprietary Ultra Shear Technology System, & Remains on Target for Commercial Release by Early 2021

 

South Easton, MA – October 6, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the achievement of a critical milestone: the lock-in of final design specifications for the commercial production model of its proprietary, next-generation Ultra Shear Technology™ (“UST™”)-based nanoemulsification system.  Following achievement of this milestone, the Company has begun to build the initial “Alpha” unit of the commercial model. Once built, tested, and approved, the Company will immediately proceed to build an additional 15 ready-for-sale systems, thus enabling PBI to meet its goal of shipping the BaroShear K45 UST System in early (Q1/Q2) 2021.

 

Based on the Company’s patented UST platform, the BaroShear K45 is a unique breakthrough nanoemulsification system designed to resolve one of the most substantive problems facing manufacturers of biotherapeutic drugs, nutraceuticals (including hemp-derived CBD products), and other products containing oil-based active ingredients that are at best poorly soluble in water.  As with any oil-based product, it is difficult for the water-based biochemistry of humans and other animals to access and absorb the active ingredients hidden within oil drops. Poor water solubility leads to lower absorption and bioavailability of active ingredients, which makes it particularly difficult to design and deliver proper dosing of the desired compound. More recently, growing science around nanoemulsion development has shown that oil-based active ingredients manufactured into high quality nanoemulsions have delivered dramatically increased absorption and bioavailability, resulting in higher quality finished products for the consumer.

 

Mr. Kenneth F. Micciche, PBI’s Director of Marketing and Sales, commented: “We are elated to have achieved this pivotal milestone in production readiness in just three short years.  Since the start of UST program in 2018, several note-worthy milestones have been achieved: from the development of the first prototype unit and its use in processing hemp-derived CBD Oil into highly stable and effective nanoemulsions; to the development of a larger scale, floor model “test bed” prototype used to generate important data on flow rates, particle sizes, novel valve designs, temperature controllers, material properties on performance and durability of system components; and finally to the determination of the final design specifications of the ready-to-sell system.”

 

Mr. Micciche continued: “Our commercialization plan for the BaroShear K45 system is initially focused on the rapidly growing hemp-derived CBD market, which is projected to reach $20 billion by 2020.  Three months ago, we announced that we had secured purchase orders for twelve (12) BaroShear K45 nanoemulsification systems. We plan to install these systems during the first half of 2021, which we believe will generate up to $3 million in revenue. Once these initial units are installed and in commercial use, we believe they will propel the close of multiple sales of additional BaroShear K45 systems during the latter half of 2021 and thereafter.”

 

It is estimated that more than 40% of all new chemical compounds developed by the pharma industry are highly insoluble in water. To be effective as potential new drugs, most such molecules need to be processed into highly water-soluble solutions. The Company believes the UST platform can play a pivotal role in fulfilling this need.  For example, PBI scientists evaluated the UST nanoemulsification platform on Prednisone, a widely prescribed corticosteroid with systemic anti-inflammatory and immunosuppressant properties.  Prednisone is sparingly soluble in water and ethanol. When processed by the UST platform, Prednisone solutions became optically clear (signifying achievement of nanoemulsion status) and remained stable for many weeks at room temperature. Other nanoemulsions using this same formulation and UST processing have been shown by PBI scientists to remain stable at room temperature for six months and longer.

 

Mr. Richard T. Schumacher, President and CEO of PBI, commented: “The data generated over the past 18 months with both our bench-top and  floor model prototypes have validated the ability of our revolutionary UST platform to create high quality, highly stable nanoemulsions of oil and water.  These exciting results support our belief that our revolutionary UST platform can help a diverse range of customers develop a vast array of new and beneficial products across many multi-million and multi-billion dollar markets, including hemp-derived CBD and other nutraceuticals, cosmetics and topical treatments, food and beverages, and biotherapeutic drugs – such as in the example of Prednisone above.  We look forward with excitement to the upcoming commercial release of our revolutionary UST-based BaroShear K45 nanoemulsification system by early (Q1/Q2) 2021.”

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences and Leica Microsystems Sign Worldwide Co-Marketing Alliance: The Power of Laser Microdissection, PBI’s PCT Platform, and Mass Spectrometry Results in Next Generation Analysis of Tumor Biopsy Tissues

Unique Combination of Proprietary Technologies for Innovative Tumor Processing Workflow Expected to Accelerate Cancer R&D with Expanded IDs of Critical Disease State Biomarkers with Higher Precision and Speed

 

South Easton, MA – June 30, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmetics, nutraceuticals, and food & beverage industries, today announced that the Company has entered into a worldwide co-marketing agreement with German-based Leica Microsystems CMS GmbH, a Danaher company. This historic alliance is expected to offer transformative new empowerment to cancer research worldwide, by integrating the latest enabling technologies in capturing, isolating, and preparing precious biopsy samples for superior analysis of relevant biomarkers of disease state and treatment response.

 

Leica Microsystems (“Leica”) is a leading global designer and producer of innovative high-tech precision optical systems for the analysis of microstructures. It is one of the market leaders in microscopy, pathology diagnostics, and surgical microscopes. Users of Leica’s instruments and services can be found in both clinical applications and broader life science research, several surgical specializations, disciplines associated with material sciences, the manufacturing industry, forensics services, and in classrooms around the world. Leica is a Danaher company.

 

PBI and Leica will co-market a novel, enabling technology platform that combines the Leica Laser Microdissection (LMD) System for precise excision of specific, minute sections of biopsy tissue with PBI’s Pressure Cycling Technology (“PCT”)-based Barocycler System for rapid protein extraction and digestion for sample preparation prior to mass spectrometry analysis. Specifically, both companies will promote an integrated biomarker discovery workflow designed to quickly and efficiently collect tissue sections excised by the Leica LMD and then drop the samples into PBI’s consumable MicroTubes for rapid PCT processing. Proteins are then analyzed by mass spectrometry (MS), the global method-of-choice for high throughput and comprehensive protein analysis.

 

The integrated workflow of LMD and PCT was developed by Dr. Thomas P. Conrads, a nationally acclaimed protein chemist.  Dr. Conrads is the Senior Director of Women’s Health Research in the Inova Women’s Service Line; he is also Chief Scientific Officer of the Women’s Health Integrated Research Center (WHIRC) at Inova Health System.

 

Dr. Conrads said: “We believe that integrating LMD, PCT, and MS will improve our understanding of the complex tissue microenvironment and better enable identification of new biomarkers.  We believe that the insights gained from applying this novel workflow will result in significant improvements in the clinical management of gynecologic and other cancers.”  The global cancer biomarker market is expected to reach $136.5 billion by 2023.

 

Ms. Roxana McCloskey, PBI’s Global Director of Sales & Marketing, said: “The generation of reliable and reproducible data from biopsy samples is difficult, as it requires the integration of multiple and varied laboratory processes, particularly tissue extraction, sample preparation, and analysis. The innovative LMD-PCT workflow enables the reproducible and rapid extraction of proteins from precious clinical samples by combining the precision of the Leica LMD system with PBI’s versatile PCT sample preparation platform.  The ability to co-market the workflow offers the opportunity for the combined sales and marketing forces of Leica and PBI to extend the integrated LMD-PCT systems into additional research centers globally that are focused on clinical proteomics, cancer research, biomarker discovery, and precision medicine.”

 

Dr. Falk Schlaudraff, Head of Application Management of Leica Microsystems, commented: “Biomarkers can be used as indicators of certain diseases, such as cancer. They also improve our understanding of the complex tumor microenvironment. There are distinct molecular differences between tumor and non-tumor regions, as well as in the tumor itself.  These critical differences can only be deciphered by isolating specific, minute sections of these regions. The combined LMD and PCT systems allow for this separation with high accuracy and speed.  Downstream molecular analysis of the different regions will be meaningful since they can be analyzed separately and not as a mixture. We are very excited to combine our LMD system with the power of PCT.”

 

Mr. Richard T. Schumacher, President and CEO of PBI, concluded: “We are delighted to see PBI’s PCT-based Barocycler system featured in a pivotal position in this important new tumor processing workflow. Based on results to date, we believe the number of laboratories worldwide performing laser microdissection followed by mass spectrometric analyses will increase at a steady and significant rate, that our Barocycler system will fulfill a critical part of this workflow, that our combined marketing and sales capabilities will result in increased market exposure and acceptance, and that the adoption of this novel new workflow should result in a measurable increase in Barocycler sales before the end of 2020.”

 

About Leica Microsystems

 

Leica Microsystems develops and manufactures microscopes and scientific instruments for the analysis of microstructures and nanostructures.  Widely recognized for optical precision and innovative technology, the company is one of the market leaders in compound and stereo microscopy, digital microscopy, confocal laser scanning and super-resolution microscopy with related imaging systems, electron microscopy sample preparation, and surgical microscopy.  Leica Microsystems is a Danaher company.

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:

http:/www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

Investor Contacts:

Richard T. Schumacher, President and CEO

(508) 230-1828 (T)

 

Roxana McCloskey, Global Director of Sales & Marketing

(508) 230-1829 (F)

 

Source: Pressure BioSciences, Inc.

$3,500,000 Initial Order for FDA-Registered, Premium Hand Sanitizer Catapults SkinScience Labs, a Pending Accretive Acquisition of Pressure BioSciences, Into the Multi-Billion Dollar Hand Sanitizer Market

SkinScience Labs, Creator of Award-Winning Dr. Denese Skin Care & Anti-Aging Product Lines, Enters Hand Sanitizer Market with Proprietary Formula Developed by Founder Adrienne Denese, MD., Ph.D.

 

South Easton, MA – June 11, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that its merger partner SkinScience Labs, Inc. has received an initial $3.5 million dollar order for its newly developed, premium, dermatological hand sanitizer product.  PBI announced plans on April 30, 2020 to acquire SkinScience Labs (SSL Acquisition), parent company of the award-winning Dr. Denese skin care and anti-aging product lines. PBI’s rights to acquire SkinScience Labs, Inc. arise through its planned acquisition of Cannaworx, Inc., announced on April 29, 2020 (Cannaworx, Inc. Acquisition).

 

Adrienne Denese, M.D., Ph.D. (Cornell, Harvard) is an industry leader in scientific skin care breakthrough technologies.  As founder of the award-winning Dr. Denese SkinScience® product lines, it has been Dr. Denese’s mission in life to help women look and feel younger, and live healthier lives. Her skin care and anti-aging product lines have consistently been top sellers on QVC, generating sales of about $18 million in 2019 and over $500 million since 2003 (https://drdenese.com).

 

Dr. Denese commented: “Our goal has always been to develop and supply the highest quality of personal care products expected by our very loyal customer base. Over the past few months, shortages of hand sanitizers have been reported by stores all over the US. With SkinScience Labs’ nearly two decades of experience in formulation, manufacturing, and distribution, and my expertise and training as a scientist and physician, it became clear that we could become an important new part of the solution. With particular focus on the adverse effects that the high alcohol content in typical hand sanitizers have on skin, we went back to the lab and formulated a premium quality, dermatologically driven hand sanitizer.  We recently made the decision to release this very effective, premium product to the market (Hand Sanitizer Launch).”

 

According to a 2019 report by Radiant Insights, the global hand sanitizer market was estimated to be $2.4 billion in 2017 and is anticipated to reach $5.5 billion by 2024 (Radiant Insights Report).

 

The merger of SkinScience Labs, Cannaworx, Inc., and Pressure BioSciences is expected to close by June 30, 2020. At that time, the company will change its name to Availa Bio.  PBI, Cannaworx, and SkinScience Labs will operate as three separate, highly synergistic divisions under the Availa Bio umbrella. The new parent company will be publicly traded as a QB company on the OTC Marketplace.  Availa Bio will be led by Jim Morrison (Availa CEO), former President of L’Oreal, StarShop, and Graham Webb.  Mr. Morrison is also renowned for his long history in working with celebrities to launch beauty and personal care lines, including Kylie Jenner, Britney Spears, Christie Brinkley, and Rob Lowe. Mr. Morrison is widely regarded as one of the top brand strategists in the personal care space worldwide.

 

Mr. Morrison said: “Dr. Adrienne Denese is an accomplished doctor, scientist, businesswoman, and skin care visionary. It therefore came as no surprise that she chose to expand her very popular cosmetics line with the addition of a premium quality hand sanitizer based on her own proprietary formulation. With the high quality and care that Adrienne famously builds into all of her products, combined with her enormously loyal customer base, we believe this very well-timed $3.5 million dollar hand sanitizer order, which we understand is an approximate four month supply for our customer, is just the beginning of a new and very exciting era for Dr. Denese SkinScience.”

 

Mr. Morrison continued: “I have been fortunate during my 30+ years in the personal care space to have gained significant experience launching products and driving sales through a myriad of retail channels worldwide. Since the May 14 announcement that we were entering the multi-billion-dollar hand sanitizer market, I have taken the opportunity to discuss our new, premium grade hand sanitizer product with several large U.S. retail outlets. The reception we received was extremely positive. We are expecting substantial on-going growth in this exciting and innovative new product line.”

 

The Letter of Intent between Cannaworx and SkinScience Labs, and the Letter of Intent between PBI and Cannaworx, Inc. are subject to certain closing conditions, including completion of all due diligence and acquisition financing.

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:  http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

 

Investor Contacts:

Richard T. Schumacher, President and CEO

(508) 230-1828 (T)

Kenneth F. Micciche, Director – UST Program

(508) 230-1829 (F)

 

SOURCE Pressure BioSciences, Inc.

Pressure BioSciences Announces First Manufacturing Build Completely Sold Out for Revolutionary UST System for Processing Hemp-Derived Cannabinoid Oil into Stable, Water-Soluble Nanoemulsions

$2.4 Million in Orders Received for 12 BaroShear K45 Systems to Be Built in Initial Manufacturing Run

 

South Easton, MA – June 4, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced the receipt of an order for the 12th and final system scheduled to be built in the Company’s initial manufacturing run of its revolutionary BaroShear™ K45 processing system. Based on the Company’s proprietary Ultra Shear Technology™ (UST™) platform, the BaroShear K45 is a unique and powerful nanoemulsification system designed to resolve one of the most critical problems facing the global hemp-derived cannabinoid industry today: how to make hemp-derived cannabinoid oil effectively soluble in water, to optimize absorption and bioavailability when consumed or applied.  The cannabidiol market is projected to exceed $20B by 2024 (Forbes, May 2019).

 

Hemp-derived cannabinoids are extracted from the hemp plant in an oil.  As with any oil-based product, it is difficult for the water-based biology of our human bodies to access and absorb the tiny hemp-derived cannabinoid molecules that are hidden within hemp oil drops. These drops remain relatively large after traditional aggressive emulsification methods, which results in poor and variable absorption levels of hemp-derived cannabinoid molecules in the body for the treatment of targeted conditions. Low or widely varying levels of hemp-derived cannabinoid absorption and biological accessibility is a critical issue that may significantly impact the bioavailability and effectiveness of the potential benefits of hemp-derived cannabinoid products on the market today.

 

The Company previously announced plans for its first manufacturing run of twelve (12) BaroShear K45 processing systems with estimated completion times during the fourth quarter of 2020. Due to inefficiencies caused by the COVID-19 pandemic, the Company now believes that all 12 systems will be completed in time for shipment and installation to occur during the first quarter of 2021.

 

Mr. Kenneth F. Micciche, Director of PBI’s UST Program, said: “The order for the last available BaroShear K45 system from our initial production run was received from an exciting young company out of Massachusetts called Canopy CBD Farms, LLC. The senior management of Canopy CBD Farms is comprised of very knowledgeable and experienced entrepreneurs and business leaders. They have already garnered the trust and loyalty of countless businesses in or entering in the commercial industrial hemp space. They use only the highest quality hemp biomass available and the latest processing technologies to meet or exceed industry standards. We are very pleased to have them as a customer.”

 

Mr. John Westlake, Founder and President of Canopy CBD Farms, LLC., commented: “Scientific data strongly supports the critical understanding that hemp-derived cannabinoid oil needs to be processed into an effectively water-soluble, long-term stable nanoemulsion to achieve the highest quality hemp-derived cannabinoid products possible. After an exhaustive review of available technologies, a thorough evaluation of UST-processed hemp-derived cannabinoid materials, and a detailed and encompassing site visit, we concluded the BaroShear K45 was unmatched in the universe of nanoemulsion processing platforms. As we are dedicated to using only the best equipment in our own manufacturing, and convinced that the BaroShear K45 will give us many competitive advantages in the marketplace, it was an easy decision for us to place this order for the 12th and last BaroShear K45 system in PBI’s initial manufacturing run.”

 

Mr. Richard T. Schumacher, President and CEO of PBI, commented: “We are extremely gratified and excited that the initial manufacturing run of our BaroShear K45 processing systems has sold out. We are also pleased that an impressive, up-and-coming company like Canopy CBD Farms was able to participate in and place an order for the final available unit in our first manufacturing run. We are confident that the BaroShear K45 will differentiate them in the marketplace with a substantial advantage over their competition.”

 

Mr. Schumacher continued: “Much progress has been made in the development of this very novel and innovative nanoemulsification processing system. We have finished the development of and run many processing cycles with the test bed.  Our team is now beginning development of the BaroShear K45 alpha (first) unit.  We expect to complete this unit by the end of September 2020 so it will be available for testing by the companies who placed the initial 12 orders. Upon their approval, we expect to ship and install all 12 BaroShear K45 systems during Q1 2021, at which point we will recognize approximately $2.4 million in revenue. This is a very exciting milestone event for all shareholders in Pressure BioSciences.”

 

About Canopy CBD Farms, LLC.

 

Canopy CBD Farms is a state licensed Massachusetts hemp processor and manufacturing company. Foreseeing the future of government regulations, we are strategically aligning ourselves with established FDA registered laboratories and manufacturers to bring the highest of standards and quality of hemp-derived CBD products. Canopy CBD farms serves pharmaceutical and medical research companies, wishing to establish white label/co-branded manufacturing partnerships with cGMP, GLP manufacturers. Our partnerships will increase wholesale and retail distribution channels, with a ready to label line of high quality, salable hemp-derived CBD products, for a variety of uses and industries.

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

 

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

Source:  Pressure BioSciences, Inc.

 

Pressure BioSciences Announces Launch of Novel, FDA Registered Immune Booster by Pending Merger Partner Cannaworx, Inc.

Patented and Proprietary, the Company’s Immune Booster is One of Very Few Hemp-Enhanced, FDA Registered Products with a Claim for Boosting the Immune System’s Effectiveness Against Invading Pathogens

 

South Easton, MA – May 28, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that its pending merger partner Cannaworx, Inc. will be launching its patented and proprietary immune booster supplement by mid-July 2020.  The Company believes that post-launch, this product could be one of the very few, and perhaps the only, OTC (over the counter), FDA registered, hemp-containing supplements with an immune booster claim.

 

The immune system is responsible for protecting the body against illness and disease. It is comprised of a complex set of components, including organs (e.g., spleen), the lymph system, antibodies, bone marrow, and white blood cells (e.g., T cells, which play an important role in the immune response).  Since the immune system’s job is to keep us healthy by defending against invaders (e.g., bacteria and viruses), it is important to keep our immune system as strong as possible. Healthy living is the primary recommended strategy to achieve this goal – but this strategy can be powerfully supplemented with high quality immune boosters. Immune boosters have become very popular in recent years; for example, it is estimated that the global immune booster market will exceed $25B by 2025.

 

The active ingredient in the Cannaworx immune booster is a patented, proprietary blend of 44 amino acid fragments from pepsin. The product has the unique and beneficial ability of significantly increasing the number of T helper cells in the human body. T helper cells serve a critical function in the human immune response as they enable macrophage cells to kill and consume bacteria, viruses, and other invaders. Consequently, the company’s product is different from most other immune boosters on the market today, as it is a novel and potent T cell stimulator, enabling the immune system to aggressively defend against invasions of disease-causing bacteria, viruses, and other pathogens.

 

Dr. Bobby Ghalili, co-founder and President of Cannaworx, commented: “To further enhance the immune boosting effect, we added hemp seed oil (no THC) to our patented formulation. Hemp seed oil is rich in essential fatty acids (e.g., omega-6 and omega-3) and antioxidants that may help fight inflammation, cancer, diabetes, and heart disease. Omega-3 is also thought to have a positive impact on the bowel microbiome as a prebiotic, providing further support to the immune system. The manufacturing process of the patented 44 amino acid fragment formulation is highly proprietary, protected, and would be nearly impossible to imitate.”

 

Dr. Ghalili continued: “At the frontline of our commercialization strategy is our novel active ingredient, our addition of hemp seed oil, and our FDA registration with an issued NDI number (1140).  We plan to introduce our unique immune booster initially to the U.S. market through the network of over 50 sales representatives who are part of the Five Leaf Labs pending acquisition announced on May 19, 2020. We are also working closely with in-coming CEO Jim Morrison to expand on-line and retail channels. With this novel patented product, its unique immune boosting capabilities, its enhanced hemp seed oil addition, and a strong sales and distribution network, we expect the upcoming launch of our immune booster to generate strong revenue immediately following its mid-July product launch.”

 

As recently announced, Cannaworx Inc., SkinScience Labs, and Pressure BioSciences, Inc. have agreed to merge into a new company that will be named Availa Bio. Availa Bio will have an opening IP portfolio of 31 issued and many more pending patents, an existing worldwide base of hundreds of corporate and thousands of retail customers, and existing revenue from multiple products already on the market.  Availa Bio will be led by Mr. Jim Morrison, the former President of L’Oréal, Sexy Hair, StarShop, and Graham Webb. Mr. Morrison is universally regarded as one of the top brand strategists in the personal care space worldwide.

 

The Letter of Intent between Cannaworx and SkinScience Labs, and the Letter of Intent between PBI and Cannaworx, Inc. are subject to certain closing conditions, including completion of all due diligence and acquisition financing.

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

 

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences Announces Launch of FDA-Registered Hand Sanitizer as First Product Developed Through Pending Merger Partners

South Easton, MA – May 14, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that following its previously announced pending merger (Click Here) and name change to Availa Bio, that the newly branded, publicly-traded company will be entering the hand sanitizer market through the founders of Cannaworx. The custom-designed, next generation, premium hand sanitizer will be the first product released under the new holding company Availa Bio.

 

The owners of privately held Cannaworx, Inc. have obtained FDA registration for the newly developed hand sanitizer, as well as an NDC (National Drug Code) number. The product is being manufactured in a fully compliant, GMP-certified facility. Initial packaging will be in 250/500 ml. bottles, with 125 ml., 1 liter, and 1gallon sizes available by Fall 2020.  The product contains 75% alcohol in a proprietary blend of other reagents.

 

Hand sanitizers are liquid, gel, or foam anti-microbial products that have been shown to be effective in killing human disease-causing pathogens (e.g., viruses, bacteria, fungi) on the hands. Most hand sanitizers use alcohol as their active and most prominent ingredient. Hand sanitizers are believed to be faster, more efficient, and easier on the skin than repeated handwashing.  They are often used when hand washing with soap and water is not convenient or possible.  According to a 2019 report by Radiant Insights, the global hand sanitizer market is expected to reach $5.5 billion by 2024 (Click Here).

 

Availa Bio will be led by Jim Morrison (Click Here), the former President of L’Oreal, Sexy Hair, StarShop, and Graham Webb.  In addition to his remarkable career at the helm of several prominent beauty and cosmeceutical companies, Mr. Morrison also has had a long and distinguished history of collaborating with celebrities to design and launch beauty and personal care lines, including Kylie Jenner, Brittany Spears, Christie Brinkley, and Rob Lowe.  Mr. Morrison is universally regarded as one of the top brand strategists in the personal care space worldwide.

 

Mr. Morrison explained the new developments: “Over the past few months, growing shortages of hand sanitizers have been reported in stores across the USA.  In addition, the opportunity to bring leading scientists in skin care and in formulations technology together into an FDA-registered premium grade dermatological hand sanitizer has been largely unanswered. In discussing these issues with the scientific and business teams of the three companies that are merging into Availa Bio, we saw the opportunity to fill a strong demand in the market with our proprietary dermatological formulation, to develop a high-quality registered hand sanitizer.”

 

The Letter of Intent between Cannaworx and SkinScience Labs, and the Letter of Intent between PBI and Cannaworx, Inc. are subject to certain closing conditions, including completion of all due diligence and acquisition financing.

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:

 

http://www.pressurebiosciences.com

 

Please visit us on Facebook, LinkedIn, and Twitter.

 

Source:  Pressure BioSciences, Inc

Former L’Oréal President Jim Morrison Appointed as CEO To Lead Availa Bio Upon Merger of Pressure BioSciences, Cannaworx and SkinScience Labs

South Easton, MA – May 7, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), today announced that personal care industry leader Jim Morrison has been appointed to serve as the new CEO of the rebranded public company, Availa Bio, upon completion of the merger with Cannaworx, SkinScience Labs and Pressure BioSciences. As part of the proposed transactions, the Company intends to change the corporation’s name to Availa Bio. Morrison has had a legendary career including numerous leadership positions in the personal care industry, most notably as President of L’Oréal. While at L’Oréal, Morrison oversaw growth that averaged more than 20% year-over-year. He engineered the acquisitions of Redken and Matrix and led the company during a period of unprecedented growth during his tenure.

 

Morrison is considered one of the top brand strategists in the personal care space. Most recently, Morrison has been CEO of StarShop, the first celebrity-driven, mobile shopping App. He launched StarShop as a partnership with the telecommunications giant SPRINT and guided the company to a successful exit earlier this year. Morrison has had a long history of working with celebrities in the beauty space and at StarShop, most notably Britney Spears, Kimora Lee Simmons, Flo Rida, Katharine McPhee, Christie Brinkley, Rob Lowe and Kylie Jenner.

 

Business Week Magazine previously wrote: “Over the last two decades, Mr. Morrison has had a profound impact on the American Beauty Industry. In the industry’s history no other executive has had the level of financial responsibility or breadth of organizational experience as Jim. His devotion to, and success within the American beauty industry is unmatched.”

 

Dr. Bobby Ghalili President of CannawoRx commented, “Jim is one of the preeminent beauty and personal care brand builders in the world today. Following his accomplishments as CEO in making Graham Webb one of the most successful startups of the 90’s, Jim led L’Oréal for almost a decade, delivering significant growth organically and through acquisitions. He also served as President and Chairman of the American Beauty Association from 1998 to 2004. Hands down, Jim is virtually unmatched in the experience and credibility we sought to lead our revolutionary products and growth vision for Availa Bio.”

 

As the incoming CEO designate for Availa Bio, Jim Morrison shared his excitement about the combined companies’ opportunities: “I have driven powerful growth across all traditional channels and moved companies into leadership positions in the beauty industry. I now have the opportunity to literally change the product development landscape of several major industries with the use of the UST Technology in the proliferation of new products that are expected to have greater bioavailability and efficacy than anything in the world today. I see Availa Bio as a transformational company. The chance to work with Drs. Bobby Ghalili and Adrienne Denese creates a dynamic synergy. My background in skin care, the incredible SkinScience brand, and my track record in launching new products into the market presents a very rare opportunity. Availa Bio will allow me to bring over 30 years of experience and my professional network to focus on revolutionary value creation for this powerful new entity.”

 

Dr. Adrienne Denese, President of SkinScience Labs, Inc., stated, “Jim Morrison has been astonishingly successful in building skin care brands for major celebrities. Having achieved over $500 million in sales over a seventeen-year period, I am very proud of the track record and very loyal customer following that I have built under the Dr. Denese SkinScience brand. I could not be more excited at the prospect of teaming up with Jim to take these products and our new UST technology to much greater heights and many new customers, through both existing QVC and additional new channels.”

 

Commenting on the appointment, PBI’s current President & CEO Richard T. Schumacher stated, “Availa Bio will use PBI’s breakthrough Ultra Shear Technology™ (“UST™”) to process oil-based nutrients and therapies into more effective, water-soluble solutions. We believe this will revolutionize Availa’s extensive line of existing and new personal care and consumption products, extending from human into veterinary and agricultural applications. We are honored to have Jim’s expertise, experience, and leadership as we enter into this new phase of expected explosive growth for these products, both through current sales channels like QVC, as well as through many new paths of retail distribution and online shopping.”

 

The Letter of Intent between CannawoRx and SkinScience Labs, and the Letter of Intent between PBI and CannawoRx, Inc. are subject to certain closing conditions, including completion of all due diligence and acquisition financing.

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements
This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.

 

Source: Pressure BioSciences, Inc.

Pressure BioSciences Announces Planned Name Change to “Availa Bio” Following Completion of Cannaworx and SkinScience Labs Acquisitions

Merged Companies to Operate as Synergistic Divisions. New Corporate Identity Focuses on Optimizing Bioavailability, Absorption, Quality and Performance of Human, Animal and Agricultural Products.

 

South Easton, MA – May 5, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced its intention to change the corporation’s name to Availa Bio upon completion of the acquisitions and merger of Cannaworx, Inc. and SkinScience Labs, Inc. with PBI.  The three companies will operate as synergistic divisions within the combined “Availa Bio” entity.  This strategic change in corporate identity and branding reflects the science-driven collaboration of the companies focused on the overarching priority of leveraging the revolutionary Ultra Shear Technology™(UST™) platform to bring significant new value to consumers in optimized bioavailability, absorption, quality and performance across Availa Bio’s diverse range of human, animal and agricultural products being introduced in the coming months or already on market.

 

Mr. Richard T. Schumacher, President and CEO of PBI, explained: “PBI’s UST platform offers the potential to deliver an extraordinary breakthrough in creating unique, high quality nanoemulsions of oil in water.  A vast range of personal care and consumption products, including nutraceuticals, cosmetics, pharmaceuticals, food & beverages, all face the perplexing challenge of getting active oil-based nutrients or therapeutic ingredients to become easily absorbable and effective in the water-based biology of our bodies.  The opportunity to combine our strong engineering and biotech capabilities with two companies that already provide product innovation and brand leadership in diverse consumer product areas is very exciting and allows us to clearly move the identity and market focus of the combined companies from science platforms to the value delivery of availability and performance of active ingredients in final products.”

 

Dr. Bobby Ghalili, President of Cannaworx, Inc., expanded: “My co-founder in Cannaworx is Dr. Adrienne Denese, MD, Ph.D., the founder, innovator and spokesperson behind over $500M in Dr. Denese SkinScience product line sales for the past 17 years on QVC. These skin care and anti-aging products are part of our planned rollup of companies under Availa Bio.  In our rapidly expanding line of innovative human, veterinary and agricultural products, several of which incorporate phytocannabinoids from hemp oil, we are utilizing our own oral and topical proprietary bioavailability and absorption delivery technology. The UST platform will now allow us to deliver high performance nanoemulsions, further increasing both bioavailability and absorption rates. Our planned rollout of Cannaworx products over the coming months includes two patented oral phytocannabinoid formulations that incorporate indications for pain relief allowed under an FDA OTC monograph. We believe our combined portfolios of intellectual property will give Availa Bio a significant competitive advantage within the industries we serve.”

 

With an IP Estate of 31 issued and an additional dozen or more pending patents, an existing worldwide base of hundreds of corporate and thousands of retail customers, multiple products already on the market with many more expected to be launched in the weeks and months ahead, Availa Bio plans to disrupt large, addressable markets, as it marches toward profitability and increased shareholder value. The markets expected to be served include: the U.S. hemp-derived CBD market (anticipated to reach $23.7 billion by 2023), the international cosmetics market (projected at $758 billion by 2025), the global biopharmaceuticals market (expected to reach $389 billion by 2024),  the global food & agriculture technology and products market (estimated at $729 billion by 2023), and the worldwide food and beverage market.

 

Dr. Denese, President of SkinScience Labs, added her enthusiasm for the combination of the three companies: “My decades of development and marketing of skin care and anti-aging products that meet the scrutiny and demands of an extremely loyal following of consumers has always required us to be leaders in quality and performance, not just for results but in the entire product experience perceived by our users.  We quickly realized that the Ultra Sheer Technology platform offered the opportunity to improve not only the performance of our existing, highly-regarded formulations, but also to achieve new heights within the entire cosmetics industry.”

 

The Letter of Intent between Cannaworx, Inc. and SSL, and the Letter of Intent between PBI and Cannaworx, Inc. are subject to certain closing conditions, including completion of all due diligence and acquisition financing.

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

Source: Pressure BioSciences, Inc.

Pressure BioSciences, Through Cannaworx, Inc., Announces Letter of Intent to Acquire SkinScience Labs, Inc.

Accretive Acquisition Adds Profitable Award-Winning Dr. Denese Skin Care & Anti-Aging Lines, Which Generated Approximately $18 Million in Total Sales in 2019 and Over $500M in Sales on QVC Over the Last 17 Years

 

South Easton, MA –  April 30, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced plans letter to intent to acquire SkinScience Labs, Inc., parent company of the award-winning Dr. Denese skin care and anti-aging product lines.  The rights to acquire SkinScience Labs, Inc., which includes Dr. Denese SkinScience, is through Cannaworx, Inc.  PBI announced plans on April 28, 2020 to acquire Cannaworx, Inc. (Click here).

 

Dr. Adrienne Denese, M.D., Ph.D. (Cornell, Harvard) is an industry leader in scientific skin care breakthrough technologies.  Dr. Denese, an accomplished doctor, businesswoman, and skin care visionary, is the creator of the award-winning Dr. Denese SkinScience®.  Dr. Denese has made it her life’s mission to help women look younger, feel younger, and live healthier lives.  Over the past 17 years, her skin care and anti-aging product lines have been top sellers on QVC, generating approximately $18 million in sales in 2019 and approximately $500 million in sales over the past 17 years  (https://drdenese.com).

 

Mr. Richard T. Schumacher, President and CEO of PBI, said: “The Dr. Denese SkinScience brand has reached top performing status on QVC for a skin care line, selling over 25 million units and receiving multiple QVC customer choice beauty awards.  Adrienne’s tremendous brand recognition, regularly repeating customer base, and major existing sales momentum brings immediate accretive impact into the PBI portfolio – and we know that our UST nanoemulsions will create powerful new leverage and opportunities for her expanding product lines.  Our team has worked very hard to bring this pivotal transition together for PBI and its shareholders, and we are very excited about the prospects for growth and value appreciation in our combined companies going forward.”

 

The Dr. Denese SkinScience product lines will leverage PBI’s Ultra Shear Technology (UST) for preparing nanoemulsions, to propel their product lines through new frontiers in product quality and effectiveness, for both existing cosmetics formulations and the introduction of new nutritional and therapeutic components that clearly reposition them into the rapidly emerging cosmeceuticals applications arena.

 

Dr. Bobby (Babak) Ghalili partnered with Dr. Denese to create Cannaworx, Inc., bringing their combined medical and product design innovation backgrounds together to build a wide portfolio of products for Cannaworx in the cosmeceuticals industry. Dr. Ghalili added: “We are very proud to have a luminary like Dr. Denese bringing her vision and dedication to breakthrough innovations and quality in skin care and anti-aging products, and her large and loyal following of dedicated customers into our new, combined company.”

 

Adrienne Denese, MD., Ph.D., characterized the compelling case for combining the three companies: “Our strong long-term repeating sales across a wide range of skin care & anti-aging products has been achieved with a passion for optimizing the consumer’s experience and outcomes with our products.  The potential for PBI’s UST platform to deliver ultra-low nanoemulsions that yield higher and more consistent bioavailability of nutrients and therapies, while minimizing the need for added stabilizers and improving safety, created an undeniably convincing case for applying it to our products.  In addition, we believe PBI’s UST process will drive the nanoemulsion droplet sizes so small they not only will deliver new levels of silkiness, absorbability, and appeal, but should also turn previously cloudy mixtures into high quality transparent products.”

 

The Letter of Intent between Cannaworx and SSL is subject to certain closing conditions, including completion of all due diligence and acquisition financing.

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

 

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

Source:  Pressure BioSciences, Inc.

 

Pressure BioSciences Announces Plans to Acquire Cannaworx, Inc.

Merger Combines Cannaworx’s Proprietary Portfolio of Innovative Consumer Products  with the Application of PBI’s Breakthrough Ultra Shear Technology in the Pain Relief, Cosmeceuticals, Nutraceuticals, Pharmaceuticals, Agriculture, and Veterinary Fields

  

South Easton, MA – April 29, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, cosmeceuticals, nutraceuticals, and food & beverage industries, today announced that it has signed a binding letter of intent to merge with Cannaworx, Inc. (USA) and its diverse portfolio of products and intellectual property developed by its founders Bobby Ghalili, DMD and Adrienne Denese, MD, PhD.

 

Drs. Ghalili & Denese bring extensive medical expertise and product innovation, along with a successful multi-year track record of developing and selling personal care and nutrition products into the newly combined public company. Currently, Cannaworx and its principals have twelve products, including several novel products that utilize the company’s patented/patent pending, full and partial spectrum, hemp-derived phytocannabinoid formulations for pain relief. Cannaworx plans to launch many of these products in 2020, two of which with a pain indication allowed under an FDA OTC monograph, which the company believes will make them the only oral hemp-derived phytocannabinoid-containing products available in today’s market with such a claim. (www.cannaworx.io)

 

Post-merger, Cannaworx products will utilize PBI’s proprietary Ultra Shear Technology™ (UST™) platform. UST is a revolutionary, patented method for processing oil-based products (e.g., hemp-derived CBD oil in water) into long-term stable, highly bioabsorbable, top quality nanoemulsions PBI UST CBD Video 022720. The Company believes UST processing will further increase the bioavailability and efficacy of the Cannaworx human, veterinary, and agricultural products; reduce manufacturing costs; increase profit margins; and distinguish the Cannaworx product lines for quality and performance within multiple markets.

 

Mr. Richard T. Schumacher, President and CEO of PBI, said: “We have been actively searching for an opportunity to participate in the end-product growth and upside we believe our UST platform creates and delivers. We are very excited to bring our companies together for what we believe to be a momentous inflection point in significant new growth and increased shareholder value.”

 

Now equipped with an extensive intellectual property portfolio utilizing a proprietary pressure platform, nanotechnology and advanced delivery systems, the merged company plans to disrupt large, addressable markets, including the U.S. hemp-derived CBD market, which is anticipated to reach $23.7 billion by 2023. In addition, the merged company is targeting the international cosmetics market (projected at $758 billion by 2025), the global biopharmaceuticals market (expected to reach $389 billion by 2024),  the global food & agriculture technology and products market (estimated at $729 billion by 2023), and the worldwide food and beverage market.

 

Dr. Ghalili described the vision and motivation behind the decision to merge Cannaworx into PBI:  “We have worked for years to bring state-of-the-art effectiveness to the formulation of a diversity of human and veterinary products that were created to deliver oil-based nutrients and therapies into the water-based biology of humans and animals. Our plan to introduce a variety of important, health-promoting phytocannabinoid ingredients into these products multiplied the challenge of achieving water-solubility for these oil-based components. As we evaluated technologies for achieving effective nanoemulsion delivery of oil-based materials in water, we discovered that PBI’s UST platform was in a class of its own, clearly out-performing all competing technologies evaluated. The opportunity to combine our capabilities, products, intellectual property, marketing and distribution channels, and proprietary methods with those of PBI was an astonishingly valuable opportunity to leverage and enable our product lines for real differentiation in our served markets and to help propel significant growth.”

 

The binding letter of intent executed between the companies details the milestones that need to be met to complete the transaction, including the completion of all due diligence and acquisition financing.

 

About Pressure BioSciences, Inc.

 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

 

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences Nearing Complete Sellout on Pre-Launch Offering of Game-Changing UST System for Processing CBD Oil into Water-Soluble Nanoemulsions

Company Receives Order for Proprietary BaroShear K45 System from Can B Corp, a Rapidly Growing Health and Wellness Company Dedicated to Delivering Only the Highest Quality CBD Products Nationwide

 

South Easton, MA  – March 12, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company has received a purchase order from a new customer, Can B Corp (OTC: CANBD), for one of its proprietary BaroShear K45 Ultra Shear Technology™ (“UST™”)-based systems for processing CBD Oil into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water. Such nanoemulsions are expected to exhibit levels of bioavailability that far exceed the absorption efficiency of today’s macro or microemulsions of CBD Oil.

 

CBD is extracted from the hemp plant in an oil.  As with any oil-based product, it is difficult for the water-based biology of human bodies to access and absorb CBD molecules from relatively large hemp oil droplets. These poor and variable absorption levels of CBD result in low and variable bioavailability of the CBD molecules available in the body for the treatment of targeted conditions. Low or widely varying levels of CBD absorption and bioavailability may significantly impact the effective delivery of the potential benefits of many CBD products on the market today.

 

Mr. Marco Alfonsi, CEO of Can B Corp, said: “It is apparent to us that PBI’s breakthrough UST platform is emerging as a pivotal market-changing technology enabling a new generation of CBD and other cannabinoid products to more effectively meet supplier objectives and consumer demands. Offering effective water solubility of cannabinoids, PBI’s UST-based BaroShear K45 system is expected to produce high CBD absorption rates and bioavailability from ingestion or topical application of cannabinoid products.”

 

Mr. Alfonsi concluded: “We look forward with anticipation to the delivery of the BaroShear K45 system in Q4 2020.  We are excited to be one of only a handful of companies worldwide that will be among the first to have the ability to process cannabinoid products with this revolutionary nanoemulsification system.  We believe the UST-based BaroShear K45 will allow us to reach levels of absorption and bioavailability in our products that far exceed that of other manufacturers on the market today.”

 

Mr. Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc., commented: “Importantly, the optimized effectiveness for the consumer also translates into allowing top-shelf manufacturers like Can B Corp to achieve targeted product effects from much lower levels of cannabinoids in their marketed products.  This should offer them a dramatic new cost efficiency, for both ingested or topically applied products. We also believe that Can B Corp’s routine use of our BaroShear K45 system will allow them to increase even more the current high-quality level of their products.”

 

Pressure BioSciences’ Board Chairman, Jeffrey N. Peterson, framed a larger perspective: “When I first discovered PBI’s unique high-pressure technologies being applied to extremely challenging life sciences problems many years ago, my chemical engineering education at MIT suddenly stood at attention.  The insights of thermodynamics illuminated a wide range of valuable application possibilities extending far beyond PBI’s initial and successful breakthroughs as a “gentle giant” in sample preparation required by thousands of scientists prior to analytical testing.  A decade later, our innovation of Ultra Shear Technology is allowing valuable materials that exist as oils (and thus do not naturally mix with water) to finally be prepared in effectively water soluble preparations that can be easily absorbed by the water-based biology of our bodies, without requiring heavy use of undesirable chemical additives.”

 

Mr. Peterson continued: “In addition to playing a significant role in the projected $89 billion (by 2024) cannabinoids market (https://mordorintelligence.com/industry-reports/cannabis-market), we expect our patented UST technology platform to transform a vast range of applications that extend across many multi-billion dollar markets, from dairy and other foods/beverages, to pharmaceuticals, nutraceuticals, and industrial applications.  As the UST platform propels PBI into these large and exciting market opportunities, we believe there will be steadily increasing shareholder and market value realization.”

 

About Can B Corp.

Can B Corp (OTC: CANBD) is a Health & Wellness company dedicated to delivering the highest quality CBD products, nutritionals, consumer products, and related medical equipment. Products are sold to consumers online, via retailers, marketing partners, events, and through doctors and other medical and health & wellness organizations. Our products are designed, grown, and produced to the highest industry standards to promote wellness and reduce pain, inflammation, anxiety, sleep disorders and related issues. Further, we are committed to serving our customers and marketing partners, with not only the best products, but the best service and experience in the marketplace now and in the future. Can B Corp owns and operates a manufacturing facility under Pure Health Products in Lacey, Washington where all CBD based products are blended and packaged. Can B Corp owns and operates Duramed Inc, which sells medical supplies and devices. Can B Corp owns and operates NY Hemp Depot and Green Grow Farms, which are licensed to grow and cultivate hemp in the State of New York.

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

 

For more information about PBI and this press release, please click on the following website link:  http://www.pressurebiosciences.com

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences Launches New Era in Preparation of Water-Soluble Nanoemulsions, for CBD and Other Valuable Oils, with Opening of UST Demonstration Laboratory

NEW UST Video Release – Solving Complex Formulation & Processing Challenges By Creating High Quality CBD Oil Nanoemulsions Using Physics not Chemistry

 

South Easton, MA, February 27, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide biotechnology, biotherapeutics, and other industries, today announced the official opening of its new Ultra Shear Technology™ (“UST™”) Demonstration Laboratory (the “UST Demo Lab”).  The UST Demo Lab is located in the Company’s South Easton, Massachusetts facility.

 

A major purpose of the UST Demo Lab is to showcase the ability of the Company’s revolutionary UST Platform to process CBD oil into true, high quality, water-soluble nanoemulsions. It is expected that nanoemulsions of CBD will be more stable, have superior aesthetic quality, and offer higher bioavailability than the standard macro/microemulsions used in most CBD products today (Nanoemulsions, in Handbook of Nanomaterials in Industrial Applications, Ghodake and Patravale, 2018).  A second purpose is to invite potential purchasers of the Company’s UST-based BaroShear Systems (initial release expected Q4 2020) to evaluate how their CBD and other product formulations work with the Company’s revolutionary UST platform.

 

This Company today released a new short video demonstrating how CBD oil from an independent manufacturer was processed into a clear, water-soluble nanoemulsion using a UST-based, first generation BaroShear system. The video shows the CBD oil and water mixture prior to and after UST processing.

 

Link to new short video showcasing the UST Demonstration Lab: PBI UST CBD Video 022720

 

CBD and other cannabinoids are extracted from the hemp plant in an oil form. The water-based biology of human bodies has difficulty accessing and absorbing oily molecules from ingested or topically applied hemp oil drops.  According to Jason Ellis, President of Vegas CBD Factory, “My colleagues in the cannabis market are beginning to realize that high quality CBD products will only come by using high quality, water-soluble nanoemulsions of CBD oil, such as those generated from processing CBD Oil with PBI’s UST™ platform, which I have observed first-hand in their lab.”

 

Kenneth F. Micciche, Director of PBI’s UST Program, said: “We processed samples of CBD oil formulations from several highly interested companies over the past two months, in an effort to optimize the service we announced today.  The results speak for themselves: one group (Vegas CBD Factory) ordered six BaroShear K45 systems (for Q4 2020 delivery and installation).  We believe several more companies who participated in the early evaluation process are close to giving us their purchase orders.  The ability to showcase the UST platform in real life, and see the final product first-hand, has been shown to be vital to our marketing efforts.  As has been said in the past: ‘build it and they will come’. The opening of the UST Demo Lab is a critical accomplishment in our UST sales and marketing strategy.”

 

Richard T. Schumacher, President and CEO of PBI commented: “The initial reactions from manufacturers of topical and ingestible cannabidiol products processed in our lab during the trial period have been extremely positive. They quickly saw how they could realize substantial cost reductions while eliminating the overloading of poorly water-soluble CBD and other cannabinoids into products to achieve targeted dosing levels. We believe our breakthrough technology platform provides them with a new-found ability to provide safe and effective dosing for their customers, which in turn should stimulate greater growth in the market for CBD-based products overall, and strong sales of our BaroShear product line when it is released to the market later this year.”

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:

 

http://www.pressurebiosciences.com

 

Please visit us on Facebook, LinkedIn, and Twitter.

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences Accelerating Rollout of Proprietary UST Platform for Water-Soluble CBD with Planned Release of Additional BaroShear Instrument

Introduction of New Benchtop, R&D Scale, UST-Based “BaroShear Mini” in Q3 2020 Expected to Speed Market Penetration of PBI’s UST Platform for Processing CBD and Other Oils  into Stable, High Quality, Water-Soluble Nanoemulsions

 

New Instrument for Product Formulation and Development to Address Many Large and Diverse Markets 

 

South Easton, MA – January 30, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company plans to release a benchtop, R&D scale, Ultra Shear Technology™ (“UST™”)-based BaroShear instrument to the market in the third quarter of 2020.  The Company believes this new instrument will address a significant un-met need in product formulation and development laboratories in the cannabis, cosmetics, nutraceuticals, pharmaceuticals, and other large and diverse markets for processing CBD and other oils into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water.

 

CBD and other cannabinoids are extracted from the hemp plant in an oil form.  The water-based biology of human bodies has difficulty accessing and absorbing oily molecules from the surface of ingested or topically applied hemp oil droplets. The ultra-low droplet sizes created by UST in nanoemulsions are designed to deliver levels of bioavailability and effectiveness that far exceed the dosing efficiencies achieved from today’s macro or microemulsions of CBD Oil.

 

Kenneth F. Micciche, Director of PBI’s UST Program, said: “We are very excited about the planned release later this year of the third instrument in the BaroShear product family. The aggressive marketing campaign we have underway for the pre-sale of our BaroShear K45 system and for the 2021 release of our industrial-scale BaroShear Max instrument has been well received by manufacturing laboratories. However, it has become apparent that product research and development labs prefer a smaller, bench-top, lower price-point, minimal throughput UST-based instrument. The BaroShear Mini clearly answers that need and will do so without cannibalizing sales to larger manufacturing facilities.  We believe this new instrument will add significantly to PBI’s revenue in 2020.”

 

Richard T. Schumacher, President and CEO of PBI commented: “It has become apparent that Pressure BioSciences’ breakthrough UST platform is a potential market-changing technology enabling a new generation of CBD and other cannabinoid products to more effectively meet consumer and supplier objectives.  By delivering effective water solubility of cannabinoids, PBI’s UST offers the promise of high absorption rates and bioavailability from ingestion or topical application of cannabinoid products. Most importantly, this delivers new confidence in controlled, safe and effective dosing for consumers.  It also offers substantial cost reductions achieved as suppliers can eliminate the overloading of CBD and other cannabinoids into products, previously required to achieve targeted dosing levels.”

 

Jeffrey N. Peterson, PBI Board Chairman, said: “Our innovation of the UST platform offers the potential to allow a universe of valuable materials that exist as oils (and thus do not naturally mix with water) to be delivered in effectively water-soluble preparations that can be easily absorbed by the water-based biology of humans and other animals, or applied in industrial and consumer applications, without requiring heavy use of undesirable chemical additives.”

 

Mr. Peterson continued: “We believe that PBI will transform a vast range of applications with UST, that extend across multiple very large markets from dairy and other foods/beverages, to pharmaceuticals, nutriceuticals, and industrial applications.  This is the technology platform that we believe will propel PBI into multi-billion dollar market opportunities, with resulting market value realization for our shareholders.”

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

 

For more information about PBI and this press release, please click on the following website link:

 

http://www.pressurebiosciences.com

 

Please visit us on Facebook, LinkedIn, and Twitter.

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences Announces Significant New Order and Near Sellout on Revolutionary Nanoemulsification System for Water-Soluble CBD Oil

New Order for Six BaroShear K45 Systems Brings Total to Nine Orders Received for Company’s New Ultra Shear Technology™ Based Platform. Additional Orders Expected Shortly  Would Sell Out Planned Initial Build of 12 Systems, with Approximate Total Value of $2.4 Million.

     

South Easton, MA – January 24, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company has received a purchase order from a new customer for six (6) proprietary Ultra Shear Technology™ (“UST™”)-based nanoemulsification systems for processing CBD Oil into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water. Such nanoemulsions are expected to exhibit levels of bioavailability that far exceed the bioavailability of today’s macro or microemulsions of CBD Oil.

 

CBD is extracted from the hemp plant in an oil.  As with any oil-based product, it is difficult for the water-based biology of the human body to access and absorb CBD molecules from relatively large hemp oil drops.  This poor and variable absorption of CBD results in low and variable bioavailability of the CBD molecule in the body. Low or widely varying levels of absorption and bioavailability of CBD adversely impacts the effective delivery of the potential benefits of many CBD products on the market today.

 

The purchase order for six BaroShear K45 systems was placed by Mr. Jason Ellis, President of Vegas CBD Factory.  When asked about his order, Mr. Ellis commented: “As consumers rush to try, use and adopt CBD-infused products, it is important to realize that the CBD in the product should be in a high-quality, water-soluble and reliably dosed form.  Proper dosing levels with high bioavailability of CBD from ingested products will in turn increase the chance for the consumer to achieve and optimize the potential beneficial effects of the CBD.”

 

Mr. Ellis continued: “Understanding and addressing this issue is a pivotal challenge for the CBD industry. At Vegas CBD Factory, we have spent a significant amount of time searching for the best method available to make high-quality nanoemulsions of CBD oil.  We have concluded that PBI’s proprietary UST-based platform is the best technology available for achieving optimized dosing and have concluded that to give our customers the best CBD-based product, we should be processing our material using the BaroShear K45 nanoemulsification platform.  Consequently, we have placed an initial order for six K45 systems.”

 

Kenneth F. Micciche, Director of PBI’s UST Program, said: “Recent BaroShear K45 instrument development efforts and demonstrations have propelled a refreshed sales effort for this innovative instrument system since the beginning of 2020. In the first three weeks of this new marketing initiative, we have secured an order for six BaroShear K45 systems and have genuine interest in additional purchases for many more units. We are excited and inspired to see our aggressive new marketing efforts for the BaroShear K45 taking such a strong early hold, and we anticipate further significant orders in the days and weeks ahead.”

 

Richard T. Schumacher, President and CEO of PBI, commented: “In addition to the new order for six BaroShear K45 systems, there are numerous additional groups who have shown high levels of interest in acquiring the new BaroShear K45 nanoemulsification system.  Our team is diligently following up with these interested parties; we believe that several of these groups will be placing purchase orders with us in the very near future. These are very exciting times for all PBI stakeholders.”

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

 

 

For more information about PBI and this press release, please click on the following website link:  http://www.pressurebiosciences.com

 

Investor Contacts:

Richard T. Schumacher, President and CEO

(508) 230-1828

Kenneth F. Micciche, Director – UST Program    

(508) 230-1829

 

Source:  Pressure BioSciences, Inc.

Pressure BioSciences' Revolutionary UST Platform Featured in Leading North American Cannabis Magazine

Cannabis Brightline Article Highlights Potential of PBI’s UST Platform to Play Significant Role in Multiple Billion Dollar Markets – Including CBD, Cosmetics, Nutraceuticals, Biopharmaceuticals, and Food/Beverage

 

South Easton, MA – January 17, 2020 – Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced that the Company’s new and innovative Ultra Shear Technology™ (“UST™”) platform was featured in Cannabis Brightline, one of North America’s leading cannabis publications. The article was written and published by Focus Media Group (FMG) of Halifax, NS, Canada.

 

Jason Ellis, President of Vegas CBD Factory, is a recognized expert in the manufacture of cannabinoid-based products. Vegas CBD Factory is located in a 70,000 sq. ft. cGMP and FDA-compliant, state-of-the-art facility in Las Vegas, NV. Mr. Ellis said: “This article highlights a critical issue facing the cannabis market today: the low bioavailability of CBD from CBD-infused products. Because oils (including CBD oil) are not well-absorbed by the water-based systems of humans and other animals, most CBD delivered by ingestion is unfortunately flushed from the body, with very little being absorbed to provide its expected beneficial effects.”

 

Mr. Ellis continued: “The article by Cannabis Brightline is very timely, as my colleagues in the cannabis market are now beginning to realize that top quality CBD products will only be generated from using high quality, water-soluble nanoemulsions of CBD oil. I have observed first-hand how existing so-called nanoemulsions of CBD oil flatly fail to deliver effective water-solubility or absorption. Conversely, nanoemulsions created by processing CBD oil through PBI’s UST platform provided astonishingly immediate and visually apparent water solubility, which years of science tells us will lead to greatly increased bioavailability. We are now considering the purchase of multiple PBI BaroShear K45 UST nanoemulsion systems in 2020.”

 

The Cannabis Brightline article also discussed two other patented and broadly enabling technology platforms developed, owned, and marketed by PBI. In addition, it included a short summary of the important work being supported by PBI’s novel pressure-based instruments in such areas as cancer, heart disease, stroke, infectious diseases, and Alzheimer’s Disease. The article is available online and can be accessed by clicking on the following link: The Solution for Maximizing the Bioavailability of CBD and Beyond.

 

Richard T. Schumacher, President and CEO of PBI, commented: “It has been very exciting to experience the rapidly growing increase in interest in our UST-based BaroShear K45 nanoemulsification system since the first of the year. In just the past week, we have received nearly a dozen unsolicited phone calls/emails from individuals in North America and Europe. Many callers were aware that our initial build of 12 BaroShear K45 instruments is expected to begin in early 2020, and they wanted to ensure they could secure a spot on the initial build purchase list.”

 

Mr. Schumacher continued: “Because of strong and growing interest, we remain comfortable with our earlier guidance that BaroShear K45 revenue in 2020 will greatly exceed current revenue from our PCT and BaroFold platforms combined. We look forward with anticipation to the initial release of the BaroShear K45 nanoemulsification system, currently planned for September 2020.”

 

About Cannabis Brightline

With thousands of subscribers, Cannabis Brightline is one of North America’s leading publications in the cannabis industry. Cannabis has quickly grown into a major economic sector in North America. It is the mission of Cannabis Brightline to help facilitate that growth by giving readers a look into what makes industry leaders successful. We do so by connecting supporting businesses, new technologies, and amazing communities to reveal a thriving industry. Cannabis Brightline (www.cannabisbrightline.com) is written and published by Focus Media Group (Halifax, NS, Canada).

 

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

 

Investor Contacts:

Richard T. Schumacher, President and CEO, (508) 230-1828 (T)
Kenneth F. Micciche, Director – UST Program, (508) 230-1829 (F)

For more information about PBI and this press release, please click on the following website link:
http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

 

Source:  Pressure BioSciences, Inc.

About Pressure BioSciences

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. Our products/services are based on three patented, pressure-enhanced platforms: (i) Pressure Cycling Technology (“PCT”), (ii)  BaroFold Platform, and (iii) Ultra Shear Technology (“UST”).

 

To date, we have installed over 300 PCT systems in approximately 200 sites worldwide. There are over 120 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

 

The PCT Platform uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., critical steps performed by hundreds of thousands of scientists worldwide, such as cell lysis and biomolecule extraction). Our primary focus is in making our recently-released, GMP-compliant, next generation PCT-based Barocycler EXTREME instrument available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization and quality control of biotherapeutic drugs.  The PCT Platform is also used in such areas as biomarker and target discovery, soil & plant biology, anti-bioterror, and forensics. We currently have over 300 PCT instrument systems placed in over 200 academic, government, pharmaceutical, and biotech research laboratories worldwide.  There are over 120 independent publications highlighting the advantages of using the PCT Platform in scientific research studies, many from worldwide key opinion leaders. The PCT Platform is offered through the Company’s Research Products & Services Group.

 

The BaroFold Platform can be used to significantly impact and improve the quality of protein therapeutics.  It employs high pressure for the disaggregation and controlled refolding of proteins to their native structures at yields and efficiencies not achievable using existing technologies.  The BaroFold Platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy and safety for both new-drug entities and biosimilar products. The BaroFold Platform can help companies create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics. It is scaleable and practical for standard manufacturing processes. This unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality, novel protein therapeutics and lower the cost of existing formulations.  Research and manufacturing licenses are available.

 

The UST Platform is based on the use of intense shear forces from ultra-high pressure (greater than 20,000 psi) valve discharge. UST has been shown to turn hydrophobic extracts into stable, water-soluble formulations on a small, laboratory scale. The UST Platform offers the potential to produce stable nanoemulsions of oil-like products in water. Such formulations could potentially have enormous success in many markets, including inks, paints, and cosmetics, as well as in pharmaceuticals and nutraceuticals, such as medically important plant oil extracts, i.e., making CBD-enriched plant oil water soluble. We believe that UST has the potential to play a significant role in a number of commercially important areas, including (i) the creation of stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water), and (ii) the preparation of higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies, e.g., dairy products. The UST Platform is currently being developed for commercialization.

 

MANAGEMENT

Richard T. SchumacherRichard T. Schumacher

President, Chief Executive Officer and Director

Mr. Richard T. Schumacher, the founder of our Company, has served as a director of Pressure BioSciences since the formation of its legacy business, Boston Biomedica, Inc., in 1978. He has served as CEO of Pressure BioSciences since April 2004 and President since September, 2004. He previously served as CEO and Chairman of the Board of Boston Biomedica from 1992 to February, 2003 and as President from 1986 to August 1999. Mr. Schumacher served as the Director of Infectious Disease Services for Clinical Sciences Laboratory, a New England-based medical reference laboratory, from 1986 to 1988. From 1972 to 1985, Mr. Schumacher was employed by the Center for Blood Research, a nonprofit medical research institute associated with Harvard Medical School. Mr. Schumacher received a BS in Zoology from the University of New Hampshire.

 

Edmund Ting, Ph.D.Edmund Ting, Ph.D.

Senior Vice President of Engineering

Dr. Edmund Ting joined Pressure BioSciences as Senior Vice President of Engineering in April, 2006. Prior to joining the company, Dr. Ting served as the Chief Research Officer of Avure Technologies, a leading worldwide manufacturer of high pressure hydrostatic processing equipment for the food and materials processing industry, Flow International Corporation, a world leader in the ultrahigh pressure waterjet cutting technology market, and the parent company of Avure Technologies. Dr. Ting last held the position of VP of Engineering Research and Development at Flow International Corporation. Dr. Ting was also a research scientist and a group leader at Grumman Aerospace Corporation. Dr. Ting earned a BS degree in mechanical engineering from Northeastern University and a Sc.D. in materials science and engineering from the Massachusetts Institute of Technology.

 

Alexander Lazarev, Ph.D.Alexander Lazarev, Ph.D.

Chief Science Officer

Dr. Alexander Lazarev, Ph.D. joined Pressure BioSciences in April, 2006 as Director of Research and Development and was promoted to Vice President of Research and Development in March, 2007. Dr. Lazarev was promoted to Chief Science Officer in December, 2018. Prior to joining Pressure BioSciences, Dr. Lazarev worked as a Visiting Scientist at the Barnett Institute of Chemical and Biological Analysis at Northeastern University, and served as a Director of New Technology Development at Proteome Systems, Inc., where he was involved in research and development of innovative proteomic analysis applications. Dr. Lazarev previously held senior research positions at Genomic Solutions, Inc. and PhytoChem Technologies, Inc. Most of Dr. Lazarev’s scientific career has been dedicated to development of methods and applications for biochemical analysis. Dr. Lazarev has been elected as an Executive Board member of the MASSEP.org, a non-profit scientific discussion forum dedicated to the promotion and improvement of chromatography and other analytical technologies. Dr. Lazarev earned his undergraduate and graduate degrees at the University of Kazan, Russian Federation.

 

Source:  https://www.pressurebiosciences.com/

Disclaimer
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG’s intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company’s publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty six hundred dollars for Pressure BioSciences, Inc. current news coverage by the company.  FNMG HOLDS NO SHARES OF Pressure BioSciences, Inc. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.